Ftse Mib
34.112,30
-0,77%
DAX
18.496,43
-0,56%
S&P 500
5.631,22
0,28%
NASDAQ
18.472,57
0,40%
Bitcoin
62.730,99
-3,27%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Processa Pharmaceuticals Inc (PCSA) Processa Pharmaceuticals Inc (PCSA) Notizie

PCSA

Processa Pharmaceuticals (PCSA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCSA
DataOraFonteTitoloSimboloCompagnia
01/02/202422:22GlobeNewswire Inc.Processa Pharmaceuticals Announces Closing of $7.0 Million Public OfferingNASDAQ:PCSAProcessa Pharmaceuticals Inc
31/01/202422:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PCSAProcessa Pharmaceuticals Inc
30/01/202416:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PCSAProcessa Pharmaceuticals Inc
29/01/202422:15Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:PCSAProcessa Pharmaceuticals Inc
29/01/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PCSAProcessa Pharmaceuticals Inc
26/01/202415:04GlobeNewswire Inc.Processa Pharmaceuticals Announces Pricing of $7.0 Million Public OfferingNASDAQ:PCSAProcessa Pharmaceuticals Inc
25/01/202414:30GlobeNewswire Inc.Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 DosesNASDAQ:PCSAProcessa Pharmaceuticals Inc
19/01/202413:45GlobeNewswire Inc.Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast CancerNASDAQ:PCSAProcessa Pharmaceuticals Inc
18/01/202413:45GlobeNewswire Inc.Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock SplitNASDAQ:PCSAProcessa Pharmaceuticals Inc
02/01/202423:06GlobeNewswire Inc.Processa Pharmaceuticals to Present at the Biotech Showcase 2024NASDAQ:PCSAProcessa Pharmaceuticals Inc
29/12/202314:55Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PCSAProcessa Pharmaceuticals Inc
19/12/202315:00GlobeNewswire Inc.Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over CapecitabineNASDAQ:PCSAProcessa Pharmaceuticals Inc
13/12/202315:00GlobeNewswire Inc.Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation CapecitabineNASDAQ:PCSAProcessa Pharmaceuticals Inc
30/11/202314:15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the MedInvest Oncology Investor ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
29/11/202314:15GlobeNewswire Inc.Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and OutlookNASDAQ:PCSAProcessa Pharmaceuticals Inc
13/11/202322:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PCSAProcessa Pharmaceuticals Inc
13/11/202319:40GlobeNewswire Inc.Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil ThompsonNASDAQ:PCSAProcessa Pharmaceuticals Inc
09/11/202314:15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 AmericasNASDAQ:PCSAProcessa Pharmaceuticals Inc
01/11/202313:15GlobeNewswire Inc.Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion LeadersNASDAQ:PCSAProcessa Pharmaceuticals Inc
13/10/202319:08GlobeNewswire Inc.Processa Pharmaceuticals to Present at the ThinkEquity ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
05/10/202316:01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PCSAProcessa Pharmaceuticals Inc
05/10/202316:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PCSAProcessa Pharmaceuticals Inc
25/09/202322:09Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:PCSAProcessa Pharmaceuticals Inc
06/09/202314:15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
17/08/202314:05GlobeNewswire Inc.Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer CareNASDAQ:PCSAProcessa Pharmaceuticals Inc
10/08/202322:15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
09/08/202322:47Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PCSAProcessa Pharmaceuticals Inc
08/08/202314:15GlobeNewswire Inc.Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive OfficerNASDAQ:PCSAProcessa Pharmaceuticals Inc
29/06/202322:19Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PCSAProcessa Pharmaceuticals Inc
14/06/202322:15GlobeNewswire Inc.Next Generation Chemotherapy: Improved Treatment for More PatientsNASDAQ:PCSAProcessa Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCSA

La tua Cronologia

LSE
0VRF
Ubs Etf (ch)-msci Switze...
BIT
UB82CZ
Unicredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network